JPMorgan Healthcare Leaders ETF (JDOC)
$60.50
▼ -0.56 (-0.92%)
1-day change
$52.42 – $64.69
52-week range
Top 10 holdings weight48.10%
Effective number of positions29.4
Positions above 1%31
Net assets
$9.1M
Holdings
61
As of
July 31, 2026
JDOC Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
Performance as of Sept. 30, 2026
| Period | Price return | Total return |
|---|---|---|
| 1M | ▼ -3.61% | ▼ -3.61% |
| 3M | ▲ +5.98% | ▲ +5.98% |
| 6M | ▲ +5.98% | ▲ +5.98% |
| YTD | ▲ +4.59% | ▲ +4.59% |
| 1Y | ▲ +15.43% | ▲ +16.45% |
| 3Y | · | · |
| 5Y | · | · |
| Max | ▲ +4.32% | ▲ +10.68% |
Volatility 1Y17.62%
Volatility 3Y·
Max drawdown 3Y
·
Beta 3Y·
Sharpe 1Y*1.51
Total return assumes dividends are reinvested. Returns are not benchmarked against an index. * Sharpe ratio is computed with a 0% risk-free rate.
Fund flows (SEC-reported)
Last month (Jul 2026)
+$0
Quarter ending Jul 2026
-$2.8M
Trailing 12 months
-$22K
Based on the fund's own SEC Form N-PORT monthly flow disclosures (Item C.9 "Flow Information") — sales minus redemptions, reinvested distributions excluded. This is a different, independent metric from the "Net flows" estimate above (which is derived from daily shares-outstanding changes). SEC N-PORT filing lag is up to ~60 days; the most recent month/quarter may not yet be fully reflected.
Full composition 61 holdings
| Name | CUSIP | Value | % | Balance | Category | Country |
|---|---|---|---|---|---|---|
| AbbVie, Inc. | 00287Y109 | $712K | 7.85 | 2,838 | EC | US |
| Eli Lilly & Co. | 532457108 | $704K | 7.76 | 613 | EC | US |
| UnitedHealth Group, Inc. | 91324P102 | $531K | 5.85 | 1,281 | EC | US |
| Merck & Co., Inc. | 58933Y105 | $437K | 4.82 | 3,359 | EC | US |
| Johnson & Johnson | 478160104 | $437K | 4.82 | 1,706 | EC | US |
| AstraZeneca plc | · | $341K | 3.76 | 2,007 | EC | GB |
| Thermo Fisher Scientific, Inc. | 883556102 | $339K | 3.73 | 590 | EC | US |
| Bristol-Myers Squibb Co. | 110122108 | $324K | 3.57 | 4,962 | EC | US |
| Abbott Laboratories | 002824100 | $282K | 3.11 | 2,669 | EC | US |
| CVS Health Corp. | 126650100 | $257K | 2.83 | 2,458 | EC | US |
| Roche Holding AG | · | $256K | 2.82 | 586 | EC | CH |
| Novo Nordisk A/S | · | $237K | 2.61 | 5,014 | EC | DK |
| GSK plc | · | $224K | 2.47 | 8,605 | EC | GB |
| Stryker Corp. | 863667101 | $202K | 2.23 | 620 | EC | US |
| Danaher Corp. | 235851102 | $196K | 2.16 | 1,006 | EC | US |
| Cencora, Inc. | 03073E105 | $188K | 2.07 | 604 | EC | US |
| Argenx SE | · | $187K | 2.06 | 218 | EC | NL |
| Intuitive Surgical, Inc. | 46120E602 | $175K | 1.93 | 496 | EC | US |
| Edwards Lifesciences Corp. | 28176E108 | $157K | 1.73 | 1,827 | EC | US |
| IQVIA Holdings, Inc. | 46266C105 | $155K | 1.71 | 661 | EC | US |
| Teva Pharmaceutical Industries Ltd. | · | $145K | 1.60 | 4,084 | EC | IL |
| Regeneron Pharmaceuticals, Inc. | 75886F107 | $145K | 1.60 | 190 | EC | US |
| Novartis AG | · | $145K | 1.60 | 926 | EC | CH |
| Biogen, Inc. | 09062X103 | $142K | 1.56 | 699 | EC | US |
| Cardinal Health, Inc. | 14149Y108 | $137K | 1.51 | 597 | EC | US |
| Takeda Pharmaceutical Co. Ltd. | · | $117K | 1.29 | 3,400 | EC | JP |
| Centene Corp. | 15135B101 | $108K | 1.19 | 1,740 | EC | US |
| Hoya Corp. | · | $107K | 1.18 | 700 | EC | JP |
| Humana, Inc. | 444859102 | $106K | 1.16 | 290 | EC | US |
| Boston Scientific Corp. | 101137107 | $97K | 1.07 | 2,069 | EC | US |
| Fresenius SE & Co. KGaA | · | $94K | 1.04 | 1,831 | EC | DE |
| Insmed, Inc. | 457669307 | $88K | 0.97 | 894 | EC | US |
| Genmab A/S | · | $76K | 0.83 | 263 | EC | DK |
| Sartorius AG | · | $75K | 0.83 | 298 | EC | DE |
| Dyne Therapeutics, Inc. | 26818M108 | $75K | 0.82 | 2,968 | EC | US |
| Vertex Pharmaceuticals, Inc. | 92532F100 | $74K | 0.81 | 155 | EC | US |
| Spyre Therapeutics, Inc. | 00773J202 | $70K | 0.77 | 710 | EC | US |
| Neurocrine Biosciences, Inc. | 64125C109 | $67K | 0.73 | 399 | EC | US |
| Bridgebio Pharma, Inc. | 10806X102 | $66K | 0.73 | 822 | EC | US |
| Alnylam Pharmaceuticals, Inc. | 02043Q107 | $64K | 0.70 | 311 | EC | US |
| Align Technology, Inc. | 016255101 | $64K | 0.70 | 376 | EC | US |
| Charles River Laboratories International, Inc. | 159864107 | $60K | 0.66 | 259 | EC | US |
| CG oncology, Inc. | 156944100 | $56K | 0.62 | 791 | EC | US |
| Ascendis Pharma A/S | · | $53K | 0.59 | 218 | EC | DK |
| Alumis, Inc. | 022307102 | $52K | 0.57 | 1,834 | EC | US |
| LB Pharmaceuticals, Inc. | 50180M108 | $50K | 0.56 | 1,258 | EC | US |
| Disc Medicine, Inc. | 254604101 | $46K | 0.51 | 600 | EC | US |
| PTC Therapeutics, Inc. | 69366J200 | $45K | 0.49 | 658 | EC | US |
| Bicara Therapeutics, Inc. | 055477103 | $40K | 0.44 | 1,484 | EC | US |
| Arcus Biosciences, Inc. | 03969F109 | $39K | 0.43 | 1,384 | EC | US |
Sector breakdown
Dividends 4 payments
0.85%TTM yield
$0.51TTM payout / share
Annual
(est.)
| Ex-date | Amount / share |
|---|---|
| Dec. 16, 2025 | $0.5120 |
| Dec. 24, 2024 | $0.3280 |
| Dec. 16, 2024 | $2.4890 |
| Dec. 19, 2023 | $0.0800 |
Institutional owners (13F) 6 filers
Institutions that report holding this ETF in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
| Institution | Value | % of tracked 13F | Shares | Type | As of |
|---|---|---|---|---|---|
| JPMORGAN CHASE & CO | $5,353,127 | 84.53% | 88,196 | Shares | June 30, 2026 |
| CITADEL ADVISORS LLC | $449,318 | 7.10% | 7,460 | Shares | June 30, 2026 |
| Krilogy Financial LLC | $266,640 | 4.21% | 4,427 | Shares | June 30, 2026 |
| Sanctuary Advisors, LLC | $250,087 | 3.95% | 4,152 | Shares | June 30, 2026 |
| ROYAL BANK OF CANADA | $7,000 | 0.11% | 120 | Shares | June 30, 2026 |
| WELLS FARGO & COMPANY/MN | $6,384 | 0.10% | 106 | Shares | June 30, 2026 |